By Colin Kellaher
Novocure on Monday said a phase 3 study of its Tumor Treating Fields, or TTFields, therapy in combination with paclitaxel missed its primary endpoint of overall survival in patients with platinum-resistant ovarian cancer.
The oncology company said TTFields therapy was well-tolerated in the study, with no added systemic toxicities.
Novocure said that while the study results are disappointing, it is encouraged by the signal identified from an exploratory analysis that suggests the potential for a clinical benefit when TTFields therapy is initiated early in a patient’s treatment.
Trading in shares of Novocure, which closed Friday at $29.77, was halted premarket on Monday.
Write to Colin Kellaher at [email protected]
Read the full article here
